BridgeMD
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER2- Advanced Breast Cancer
EU CTIS ID: 2023-506786-63-00
What this study is testing
To compare the PFS of imlunestrant (Arm A) to the standard comparator of Investigator’s Choice Endocrine Therapy of either fulvestrant or eemestane (Arm B) in the ITT population To compare the PFS of Arm A to Arm B in the ESR1-mutation detected population To compare the PFS of imlunestrant plus abemaciclib (Arm C) to imlunestrant (Arm A) in the ITT population
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have HR+ HER2- breast cancer
- Participants must have cancer that is advanced or has spread to another part of the body
- Participants must have already received a drug that blocks the production of estrogen
- Participants must have adequate body organ function
- Participants must be in fair to good health
- Participants must be able to swallow capsules/tablets
You likely can't join if
- Participants must not have received chemotherapy or some targeted therapies for advanced breast cancer
- Participants must not have cancer that has spread to the brain that has not been treated or is causing symptoms
- Participants must not have another serious medical condition
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Argentina
- Australia
- Brazil
- Mexico
- China
- India
- Russian Federation
- Ukraine
- Korea, Republic of
- United States
- Turkey
- Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Argentina; Australia; Brazil; Mexico; China and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.